Catalyst calendar
Dated milestones from primary sources: what the companies themselves say in press releases filed with the SEC, and the primary completion dates sponsors register on ClinicalTrials.gov. Every row links to its source.
How to read this. The dates are the companies' and sponsors' own statements, shown as precisely as the source gives them (a day, a month, a quarter such as Q3 2026, a half-year such as H2 2026, or a year). They are not our forecasts, and they often move. A row is shown only after it has been checked against its source. More about primary completion. Last checked against the sources: 27 October 2026.
Company-announced milestones
Taken from the companies' own press releases. When a newer press release restates a milestone, only the newest version is shown.
| When | Company | Type | Milestone, as stated by the company | Source | Checked |
|---|---|---|---|---|---|
| 2026 | Beam Therapeutics | Data | BEAM-101: Beam Therapeutics expects to report updated data for the BEACON trial by year-end 2026. | Company press release, filed with the SEC 4 August 2026 | 27 October 2026 |
| 2026 | Beam Therapeutics | Regulatory | risto-cel: Beam Therapeutics expects to submit a biologics license application for risto-cel as early as year-end 2026. | Company press release, filed with the SEC 4 August 2026 | 27 October 2026 |
| 2026 | CRISPR Therapeutics | Data | Lp(a) program: CRISPR Therapeutics anticipates providing an update on its Lp(a) program in 2026. | Company press release, filed with the SEC 3 August 2026 | 27 October 2026 |
| H2 2026 | CRISPR Therapeutics | Data | CTX112: CRISPR Therapeutics anticipates updates from the Phase 1/2 trial of zugo-cel in B-cell malignancies in the second half of 2026. | Company press release, filed with the SEC 3 August 2026 | 27 October 2026 |
| H2 2026 | Intellia Therapeutics | Enrolment | MAGNITUDE-2: Intellia Therapeutics expects to complete enrollment in the MAGNITUDE-2 trial for ATTRv-PN in the second half of 2026. | Company press release, filed with the SEC 6 August 2026 | 27 October 2026 |
| 10 Mar 2027 | Intellia Therapeutics | FDA decision date (PDUFA) | lonvo-z: Intellia Therapeutics reports PDUFA target action date for lonvo-z set for March 10, 2027. | Company press release, filed with the SEC 8 September 2026 | 27 October 2026 |
Primary completion dates
When active studies are expected to reach primary completion, the point where the main results can be analysed. Topline results usually follow some weeks or months later. Source: ClinicalTrials.gov.
2026
| Primary completion | Company | Phase | Programme and study | Checked |
|---|---|---|---|---|
| Dec 2026 estimated |
Beam Therapeutics | Phase 1/2? | BEAM-201 · Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) · NCT05885464 |
27 October 2026 |
2027
| Primary completion | Company | Phase | Programme and study | Checked |
|---|---|---|---|---|
| 19 May 2027 estimated |
Circio Holding ASA | Phase 1/2? | TG01 · Multiple Myeloma, Smoldering Multiple Myeloma The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma · NCT05841550 |
27 October 2026 |
| Jun 2027 estimated |
CRISPR Therapeutics | Phase 1? | CTX310 · Cardiovascular, Metabolic Disease, Dyslipidemias A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias · NCT07491172 |
27 October 2026 |
| Jun 2027 estimated |
Circio Holding ASA | Phase 2? | Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer · NCT06015724 |
27 October 2026 |
| 6 Jun 2027 estimated |
CRISPR Therapeutics | Phase 3? | CTX001 · Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) · NCT05329649 |
27 October 2026 |
| 9 Jun 2027 estimated |
Vertex Pharmaceuticals | Phase 3? | CTX001 · Beta-Thalassemia, Thalassemia, Hematologic Diseases Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease · NCT05477563 |
27 October 2026 |
| Jul 2027 estimated |
Intellia Therapeutics | Phase 3? | NTLA-2001 · Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease A Phase 3 Study of NTLA-2001 in ATTRv-PN · NCT06672237 |
27 October 2026 |
| 22 Jul 2027 estimated |
Vertex Pharmaceuticals | Phase 2? | VX-407 · Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) · NCT07161037 |
27 October 2026 |
| 30 Sep 2027 estimated |
Vertex Pharmaceuticals | Phase 3? | VX-445 · Cystic Fibrosis Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older · NCT06460506 |
27 October 2026 |
| 14 Nov 2027 estimated |
CRISPR Therapeutics | Phase 3? | CTX001 · Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) · NCT05356195 |
27 October 2026 |
| Dec 2027 estimated |
Intellia Therapeutics | Phase 3? | NTLA-2001 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) · NCT06128629 |
27 October 2026 |
| 30 Dec 2027 estimated |
Beam Therapeutics | Phase 1/2? | BEAM-301 · Glycogen Storage Disease Type Ia A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) · NCT06735755 |
27 October 2026 |
| 31 Dec 2027 estimated |
Vertex Pharmaceuticals | Phase 3? | VX-880 · Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes · NCT04786262 |
27 October 2026 |
2028
| Primary completion | Company | Phase | Programme and study | Checked |
|---|---|---|---|---|
| Feb 2028 estimated |
Beam Therapeutics | Phase 1/2? | BEAM-101 · Sickle Cell Disease BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease · NCT05456880 |
27 October 2026 |
| May 2028 estimated |
Beam Therapeutics | Phase 1/2? | BEAM-302 · Alpha 1-Antitrypsin Deficiency A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) · NCT06389877 |
27 October 2026 |
| 2 Jun 2028 estimated |
Vertex Pharmaceuticals | Phase 2/3? | VX-147 · Proteinuric Kidney Disease Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease · NCT05312879 |
27 October 2026 |
| 1 Jul 2028 estimated |
CRISPR Therapeutics | Phase 1/2? | CTX340 · Hypertension A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension · NCT07758634 |
27 October 2026 |
| 29 Dec 2028 estimated |
Vertex Pharmaceuticals | Phase 2/3? | Povetacicept · Primary Membranous Nephropathy Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) · NCT07204275 |
27 October 2026 |
2029
| Primary completion | Company | Phase | Programme and study | Checked |
|---|---|---|---|---|
| 30 Jan 2029 estimated |
Vertex Pharmaceuticals | Phase 2? | VX-670 · Myotonic Dystrophy Type 1 (DM1) A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I · NCT06926621 |
27 October 2026 |
| 2 Feb 2029 estimated |
Cereno Scientific AB | Phase 2? | CS1 · Pulmonary Arterial Hypertension CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension · NCT07761572 |
27 October 2026 |
| 2 Mar 2029 estimated |
Vertex Pharmaceuticals | Phase 2? | Povetacicept · Myasthenia Gravis, Generalized A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis · NCT07501702 |
27 October 2026 |
| 30 May 2029 estimated |
Beam Therapeutics | Phase 1? | BEAM-201 · T-Cell Acute Lymphoblastic Leukemia/Lymphoma Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma · NCT06934382 |
27 October 2026 |
| 30 Jul 2029 estimated |
Vertex Pharmaceuticals | Phase 3? | VX-121 · Cystic Fibrosis Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older · NCT05844449 |
27 October 2026 |
| 28 Dec 2029 estimated |
Vertex Pharmaceuticals | Phase 3? | Povetacicept · Immunoglobulin A Nephropathy A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy · NCT07807995 |
27 October 2026 |
| 30 Dec 2029 estimated |
CRISPR Therapeutics | Phase 1/2? | CTX112 · Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease · NCT07804004 |
27 October 2026 |
2030
| Primary completion | Company | Phase | Programme and study | Checked |
|---|---|---|---|---|
| Jan 2030 estimated |
CRISPR Therapeutics | Phase 1/2? | CTX112 · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies · NCT05643742 |
27 October 2026 |
| 30 Jun 2030 estimated |
CRISPR Therapeutics | Phase 1/2? | CTX460 · Alpha-1 Antitrypsin Deficiency (AATD) A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD) · NCT07850076 |
27 October 2026 |
| 30 Jun 2030 estimated |
Vertex Pharmaceuticals | Phase 3? | VX-121 · Cystic Fibrosis Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age · NCT05422222 |
27 October 2026 |
2031
| Primary completion | Company | Phase | Programme and study | Checked |
|---|---|---|---|---|
| 31 Dec 2031 estimated |
CRISPR Therapeutics | Phase 1? | CTX112 · SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease · NCT06925542 |
27 October 2026 |
2033
| Primary completion | Company | Phase | Programme and study | Checked |
|---|---|---|---|---|
| Dec 2033 estimated |
CRISPR Therapeutics | Phase 1/2? | CTX112 · Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease · NCT07549698 |
27 October 2026 |
2034
| Primary completion | Company | Phase | Programme and study | Checked |
|---|---|---|---|---|
| 14 Aug 2034 estimated |
Intellia Therapeutics | Phase 1/2? | Hemophilia B A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B · NCT06379789 |
27 October 2026 |
2039
| Primary completion | Company | Phase | Programme and study | Checked |
|---|---|---|---|---|
| 30 Sep 2039 estimated |
CRISPR Therapeutics | Phase 3? | CTX001 · Beta-Thalassemia, Thalassemia, Sickle Cell Disease A Long-term Follow-up Study in Participants Who Received CTX001 · NCT04208529 |
27 October 2026 |
Primary completion date passed
The registered date has passed. Results may be pending, or the sponsor has not updated the record yet.
| Primary completion | Company | Phase | Programme and study | Checked |
|---|---|---|---|---|
| 4 Apr 2024 actual |
Intellia Therapeutics | Phase 1/2? | NTLA-2002 · Hereditary Angioedema NTLA-2002 in Adults With Hereditary Angioedema (HAE) · NCT05120830 |
27 October 2026 |
| Dec 2024 estimated, passed |
Circio Holding ASA | Phase 2? | TG01 · Pancreas Cancer Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer · NCT05638698 |
27 October 2026 |
| 29 Jan 2026 estimated, passed |
Beam Therapeutics | Phase 1? | BEAM-103 · Healthy Subjects, Healthy Participant Study This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects · NCT07304791 |
27 October 2026 |
| 10 Feb 2026 actual |
Intellia Therapeutics | Phase 3? | NTLA-2002 · Hereditary Angioedema HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) · NCT06634420 |
27 October 2026 |
| 21 Apr 2026 actual |
Moderna | Phase 1/2? | VX-522 · Cystic Fibrosis A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) · NCT05668741 |
27 October 2026 |